🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 71678J100 (prev. 64129T207 )
- Market Cap
- Micro Cap
- Previous Symbol
- NTRP (changed 12/2/2020)
- Previous Name
- Neurotrope, Inc.
Business: Petros Pharmaceuticals, Inc. is committed to becoming the world's leading men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to ED, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease (acute and chronic), hormone health and substance use disorders.
Notes: Dec. 2, 2020 -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men's health conditions ("Metuchen"), today announced the completion of their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement (the "Merger Agreement"). Neurotrope shareholders also approved the spin-off of substantially all of Neurotrope's existing assets, operations and liabilities, except for certain cash retained in accordance with the terms of the Merger Agreement, into a separately traded public company.
Company Contact
- CEO
- Charles Ryan
- CFO
- Robert Weinstein
- Headquarters
- 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036
- Phone
- 973-242-0005
- Investor Relations
- Robert Weinstein · 973-242-0005 · IR@PetrosPharma.com